Vimarsana
Biggest News Aggregation in the World

Page 14 - Eva Kalias News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eva Kalias. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eva Kalias Today - Breaking & Trending Today

Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Meeting - Vimarsana News

Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Meeting

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Investegate |Santhera Pharmaceuticals Holdi Announcements | Santhera Pharmaceuticals Holdi: Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Meeting - Vimarsana News

Investegate |Santhera Pharmaceuticals Holdi Announcements | Santhera Pharmaceuticals Holdi: Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Meeting

Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting

Santhera Pharmaceuticals Holding AG: Santhera to Host Investor Conference Call - Vimarsana News

Santhera Pharmaceuticals Holding AG: Santhera to Host Investor Conference Call

Pratteln, Switzerland, December 6, 2021 - Santhera Pharmaceuticals (SIX: SANN) is pleased to invite investors, shareholders, media representatives and interested parties to join a conference call

Santhera and ReveraGen Announce Positive Topline Results - Vimarsana News

Santhera and ReveraGen Announce Positive Topline Results

Ad hoc announcement pursuant to Art. 53 LR Vamorolone given throughout the study showed sustained efficacy across multiple endpoints over 48 weeks and the...

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study - Vimarsana News

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study

Ad hoc announcement pursuant to Art. 53 LR Vamorolone given throughout the study showed sustained efficacy across multiple endpoints over 48 weeks and the good safety and tolerability profile